Medical Management for BPH

The Role of Combination Therapy

Claus Roehrborn, Jeremy P W Heaton

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

An underlying scientific rationale exists for combining α-adrenergic blockade and 5α-reductase inhibition for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH), given that their modes of action in managing LUTS secondary to BPH are different and complementary. Both α-blockers and 5α-reductase inhibitors (5-ARIs) provide sustainable reductions in symptom scores. Although both classes of agents have data to support delays in acute urinary retention (AUR) and the need for invasive BPH therapy, only the 5-ARIs reduce the long-term risks of both events. Current evidence suggests that initiation of combination therapy should be considered in men with prostatic enlargement, elevated prostate-specific antigen (PSA) level, LUTS, and moderate or severe bother. The Medical Therapy of Prostate Symptoms (MTOPS) study provided evidence that the prostate volume threshold for benefit of a 5-ARI, and therefore of combination therapy, is lower than previously thought (>25 cc). Cost effectiveness in this population has been demonstrated to increase in men with severe symptoms, although transurethral resection of the prostate (TURP) is probably more favourable in the long-term from a cost perspective. However, many men wish to avoid surgery, and for them, combination therapy offers significant benefits over monotherapy, especially over α-blocker therapy where no long-term reductions in the risk of AUR or surgery have been demonstrated.

Original languageEnglish (US)
Pages (from-to)716-721
Number of pages6
JournalEuropean Urology, Supplements
Volume5
Issue number12
DOIs
StatePublished - Aug 2006

Fingerprint

Prostatic Hyperplasia
Lower Urinary Tract Symptoms
Urinary Retention
Therapeutics
Prostate
Oxidoreductases
Transurethral Resection of Prostate
Risk Reduction Behavior
Prostate-Specific Antigen
Adrenergic Agents
Cost-Benefit Analysis
Costs and Cost Analysis
Population

Keywords

  • α-blocker
  • 5α-reductase inhibitor
  • Benign prostatic hyperplasia
  • Combination therapy

ASJC Scopus subject areas

  • Urology

Cite this

Medical Management for BPH : The Role of Combination Therapy. / Roehrborn, Claus; Heaton, Jeremy P W.

In: European Urology, Supplements, Vol. 5, No. 12, 08.2006, p. 716-721.

Research output: Contribution to journalArticle

@article{a38ed79dbe854aa3b8b76c23a9bcd3bf,
title = "Medical Management for BPH: The Role of Combination Therapy",
abstract = "An underlying scientific rationale exists for combining α-adrenergic blockade and 5α-reductase inhibition for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH), given that their modes of action in managing LUTS secondary to BPH are different and complementary. Both α-blockers and 5α-reductase inhibitors (5-ARIs) provide sustainable reductions in symptom scores. Although both classes of agents have data to support delays in acute urinary retention (AUR) and the need for invasive BPH therapy, only the 5-ARIs reduce the long-term risks of both events. Current evidence suggests that initiation of combination therapy should be considered in men with prostatic enlargement, elevated prostate-specific antigen (PSA) level, LUTS, and moderate or severe bother. The Medical Therapy of Prostate Symptoms (MTOPS) study provided evidence that the prostate volume threshold for benefit of a 5-ARI, and therefore of combination therapy, is lower than previously thought (>25 cc). Cost effectiveness in this population has been demonstrated to increase in men with severe symptoms, although transurethral resection of the prostate (TURP) is probably more favourable in the long-term from a cost perspective. However, many men wish to avoid surgery, and for them, combination therapy offers significant benefits over monotherapy, especially over α-blocker therapy where no long-term reductions in the risk of AUR or surgery have been demonstrated.",
keywords = "α-blocker, 5α-reductase inhibitor, Benign prostatic hyperplasia, Combination therapy",
author = "Claus Roehrborn and Heaton, {Jeremy P W}",
year = "2006",
month = "8",
doi = "10.1016/j.eursup.2006.06.010",
language = "English (US)",
volume = "5",
pages = "716--721",
journal = "European Urology, Supplements",
issn = "1569-9056",
publisher = "Elsevier",
number = "12",

}

TY - JOUR

T1 - Medical Management for BPH

T2 - The Role of Combination Therapy

AU - Roehrborn, Claus

AU - Heaton, Jeremy P W

PY - 2006/8

Y1 - 2006/8

N2 - An underlying scientific rationale exists for combining α-adrenergic blockade and 5α-reductase inhibition for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH), given that their modes of action in managing LUTS secondary to BPH are different and complementary. Both α-blockers and 5α-reductase inhibitors (5-ARIs) provide sustainable reductions in symptom scores. Although both classes of agents have data to support delays in acute urinary retention (AUR) and the need for invasive BPH therapy, only the 5-ARIs reduce the long-term risks of both events. Current evidence suggests that initiation of combination therapy should be considered in men with prostatic enlargement, elevated prostate-specific antigen (PSA) level, LUTS, and moderate or severe bother. The Medical Therapy of Prostate Symptoms (MTOPS) study provided evidence that the prostate volume threshold for benefit of a 5-ARI, and therefore of combination therapy, is lower than previously thought (>25 cc). Cost effectiveness in this population has been demonstrated to increase in men with severe symptoms, although transurethral resection of the prostate (TURP) is probably more favourable in the long-term from a cost perspective. However, many men wish to avoid surgery, and for them, combination therapy offers significant benefits over monotherapy, especially over α-blocker therapy where no long-term reductions in the risk of AUR or surgery have been demonstrated.

AB - An underlying scientific rationale exists for combining α-adrenergic blockade and 5α-reductase inhibition for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH), given that their modes of action in managing LUTS secondary to BPH are different and complementary. Both α-blockers and 5α-reductase inhibitors (5-ARIs) provide sustainable reductions in symptom scores. Although both classes of agents have data to support delays in acute urinary retention (AUR) and the need for invasive BPH therapy, only the 5-ARIs reduce the long-term risks of both events. Current evidence suggests that initiation of combination therapy should be considered in men with prostatic enlargement, elevated prostate-specific antigen (PSA) level, LUTS, and moderate or severe bother. The Medical Therapy of Prostate Symptoms (MTOPS) study provided evidence that the prostate volume threshold for benefit of a 5-ARI, and therefore of combination therapy, is lower than previously thought (>25 cc). Cost effectiveness in this population has been demonstrated to increase in men with severe symptoms, although transurethral resection of the prostate (TURP) is probably more favourable in the long-term from a cost perspective. However, many men wish to avoid surgery, and for them, combination therapy offers significant benefits over monotherapy, especially over α-blocker therapy where no long-term reductions in the risk of AUR or surgery have been demonstrated.

KW - α-blocker

KW - 5α-reductase inhibitor

KW - Benign prostatic hyperplasia

KW - Combination therapy

UR - http://www.scopus.com/inward/record.url?scp=33746669911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746669911&partnerID=8YFLogxK

U2 - 10.1016/j.eursup.2006.06.010

DO - 10.1016/j.eursup.2006.06.010

M3 - Article

VL - 5

SP - 716

EP - 721

JO - European Urology, Supplements

JF - European Urology, Supplements

SN - 1569-9056

IS - 12

ER -